Judo Bio Launches with $100M to Pioneer Kidney-Targeted RNA Therapeutics
Key Insights
Judo Bio (search) emerges from stealth with a $100 million Series A funding round, backed by prominent investors including Atlas Venture (search), The Column Group (search), and Droia Ventures (search).
The company has developed a novel ligand-siRNA conjugate platform that specifically targets kidney cells through the megalin (search) receptor, potentially overcoming historical challenges in renal drug delivery.
Building on Alnylam's RNA interference (search) legacy, Judo Bio (search) aims to tackle both systemic conditions like diabetes (search) and kidney-specific diseases using their targeted gene silencing approach.
A new biotechnology company has emerged with ambitious plans to revolutionize kidney disease treatment through RNA interference (search) technology. Judo Bio (search), launching with $100 million in Series A funding, has developed a platform that could potentially overcome one of the biggest challenges in nephrology drug development - delivering therapeutic agents specifically to kidney cells.
The company's funding round was co-led by Atlas Venture (search), which previously incubated the startup, with participation from The Column Group (search) and Droia Ventures (search). This substantial financial backing reflects growing confidence in RNA-based therapeutic approaches for previously intractable diseases.
Innovative Platform Technology
At the heart of Judo Bio (search)'s approach lies their proprietary ligand-siRNA conjugate platform. The technology pairs small interfering RNA (siRNA) molecules with specialized targeting ligands designed to bind to megalin (search), a receptor protein found on kidney cells. This strategic targeting enables the therapeutic payload to be specifically delivered to and absorbed by kidney cells, rather than being filtered out and excreted.
"The kidney is a huge risk — in part but not entirely — because of its complexity," explains Rajiv Patni, Judo Bio (search)'s CEO. "As a drug developer, you're always thinking about a tissue target that is the holy grail."
Building on RNA Interference Legacy
Judo Bio (search)'s technology builds upon the groundbreaking RNA interference (search) field pioneered by Alnylam Pharmaceuticals (search). The company has assembled a leadership team with deep expertise in this area, including former Alnylam veteran Alfica Sehgal as Chief Scientific Officer and John Maraganore, Alnylam's former CEO, serving on the advisory board.
Unlike earlier RNA therapeutics that primarily targeted the liver, Judo Bio (search)'s platform is specifically engineered to deliver siRNA medicines to the kidney. Once inside kidney cells, these therapeutic agents work by silencing messenger RNA expression of solute carrier proteins, whose dysfunction is implicated in various kidney diseases.
Therapeutic Focus and Early Data
While specific disease targets remain undisclosed, the company is pursuing both systemic conditions such as diabetes (search) and hypertension (search), as well as kidney-specific disorders. Preliminary preclinical data, presented at the Oligonucleotide Therapeutics Society's annual meeting, demonstrate that their ligand-siRNA conjugates can achieve durable knockdown of targeted gene expression.
The company's name draws inspiration from the martial art of judo, which emphasizes turning weaknesses into strengths. Similarly, Judo Bio (search) aims to transform the kidney's complex filtering mechanism – traditionally a barrier to drug delivery – into an advantage for targeted therapeutic delivery.
Platform Potential
The technology's ability to specifically target kidney cells through the megalin (search) receptor represents a significant advance in the field of RNA therapeutics. This approach could potentially address a wide range of kidney diseases that currently lack effective treatments, while minimizing off-target effects in other tissues.